This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.

May 15, 2025

To whom it may concern:

Company	D.Western Therapeutics Institute, Inc.
Representative	Yuichi Hidaka, President and CEO
	(Code No. 4576)
Contact	Sayako Matsubara, Director
TEL	052-218-8785

Announcement of extension of joint research agreement with University of Fukui for the development of novel cataract treatments

We are pleased to announce that we have extended the joint research agreement with the University of Fukui, a National University Corporation (hereinafter “Fukui University”), for the development of novel therapeutic and preventive drugs for cataracts. The agreement, originally signed in 2024, has now been extended as of today.

Cataracts are a condition in which the crystalline lens inside the eye becomes clouded, resulting in reduced vision. They may develop due to aging, trauma, or other diseases, and are said to increase rapidly among individuals in their 60s and older in Japan. At present, the main treatment is surgery, with an estimated annual volume of over 1.6 million procedures, and the number is increasing each year.

This joint research aims to develop a new eye drop formulation as an alternative to cataract surgery. Evaluation has been underway in collaboration with Professor Masaya Oki of the Faculty of Engineering and Associate Professor Yoshihiro Takamura of the Faculty of Medical Sciences, both of the University of Fukui’s Faculties. To conduct further validation, we have decided to extend the joint research agreement.

Our company focuses on ophthalmology and actively pursues drug discovery to create new therapeutic candidates. Through early detection, prevention, and treatment of cataracts via eye drops, we aim not only to reduce the burden on patients but also to provide a broader range of treatment options. We will continue to advance this joint research accordingly.

Due to this matter, there will be no change to the earnings forecast for the fiscal year ending December 2025.

End